# About Tesa Chemical: An Editorial Digest of the Tesamorelin Record

> Tesa Chemical is an independent editorial project publishing cited summaries of the peer-reviewed tesamorelin research literature. Not a clinic, not a vendor, not a prescription.

An independent editorial project that catalogues the published tesamorelin research as a reference grid.

## What this site is

Tesa Chemical is an independent editorial project that publishes summaries of the peer-reviewed research literature on tesamorelin. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "chemical" in the name is editorial framing — a laboratory-reference posture toward the literature, the stance of someone cataloguing a research-grade GHRH(1-44) analogue on a specimen board. It is not a claim that this site dispenses, compounds, or supplies anything. There is no storefront here and no counter.

## How the digest is built

The format is deliberate: a strict nine-cell grid where each finding gets one equal-weight cell and one citation. The tesamorelin literature is unusually rectangular — discrete, quotable figures from randomized trials — so we file each datum to its source rather than blending them into prose. Pivotal trial results, pharmacokinetic analyses, the NIH LiverTox monograph, and the FDA prescribing information each occupy their own cell, and the honest caveats (efficacy established in HIV-associated lipodystrophy only, reversal on discontinuation, limited long-term oncologic data) get the same cell-weight as the efficacy figures.

Every quantitative claim on the site maps to a numbered entry on the references page. Where the data is precise, we state it precisely; where it is limited, we say so.

## What this site is not

This is not medical advice, not a treatment recommendation, and not an endorsement of tesamorelin for any use. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy; all other uses are off-label. The doses described here are doses administered in clinical research, reported as study facts — never instructions to self-administer. For the regulatory boundaries and the [side effects and contraindications](/faq), see the relevant pages, each cited to source.

---

tesamorelin catalogued cell by cell on a nine-panel reference board — every visceral-fat figure, the minutes-fast plasma clearance against the day-long IGF-1 effect, and the FDA-approved-only-for-HIV-lipodystrophy boundary filed to its study; a laboratory reference grid, not a clinic, a vendor, or a prescription.